Skip to main content
  • Saved

Commented on 's Post

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib - PubMed

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/34079282/

Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma, and the most frequent histological type is diffuse large B-cell lymphoma (DLBCL). Bruton's tyrosine kinase inhibitor (BTKi) has shown clinical activity in DLBCL. We herein report a 53-year-old man w ...

  • 1 week 6 days

    Key Points
    • In the current case report, investigators documented the successful treatment of a 53-year-old patient with refractory primary central nervous system lymphoma (PCNSL) using the small molecule inhibitor zanubrutinib.
    • “R/R PCNSL patients have a dire prognosis: a median OS of 2–3 months, regardless of the lines of salvage treatment, was found in a large-scale prospective cohort study.16 Several recent studies indicated that a relatively high objective response rate can be achieved for R/R PCNSL patients who received ibrutinib, alone or combined with other therapies. To the best of our knowledge, no case has previously been reported with treatment of these patients with zanubrutinib,” the authors wrote.
    • The authors explained that due to its low incidence and difficult clinical diagnosis, large clinical trials involving PCNSL are challenging to perform. Nevertheless, several high-powered clinical trials to identify genetic subtypes and explore the pathogenesis of DLBCL have been undertaken. Because more than 90% of PCNSL cases are of B-cell origin, results of these recent DLBCL trials have proven applicable. The authors suggested that such data could help with the personalized care of PCNSL.
    • “[W]e report a first, successful case of refractory PCNSL treated with zanubrutinib according to the NGS results. Over the next few years, we will likely see small molecules, such as zanubrutinib, being selectively integrated into first-line regimens of PCNSL to enhance curative effect and reduce recurrence,” the authors concluded.

  • 2 weeks 1 day
    Clinically useful article demonstrating that a next gen btki can penetrate cns and treat pcns....